The full repertoire of recurrent genetic lesions associated with acute myeloid leukemia (AML) is now likely known, but the pathogenic contribution of each remains incompletely understood. Some are compatible with otherwise normal hematopoiesis. For example, aging humans with normal blood counts often exhibit hematopoietic sub-clones with mutations in DNMT3A, ASXL1 or TET2, among others, even though only a small minority ever develops myeloid malignancy. [1] [2] [3] This suggests that such genetic lesions confer a competitive advantage to hematopoietic stem and progenitor cells to facilitate formation of a pre-leukemic stem cell pool receptive to secondary mutations for full-fledged leukemic transformation. 4 Consistent with this, DNMT3A mutations often persist in blood many years after successful chemotherapy for AML. 5 Conversely, other genetic lesions appear tightly associated with malignant transformation. For example, mutations in NPM1 are not seen with aging and their persistence following chemotherapy predicts for impending relapse. 6 Mutations in IDH1 and IDH2 are found in 15-20% of patients with AML 7 but are extremely rare drivers of clonal hematopoiesis in aging (~100-fold less frequent than mutations in DNMT3A, for example). [1] [2] [3] It is currently unclear whether IDH mutant (IDH mut ) clones persist in longterm clinical remission, and if so, what is their natural history, clinical fate, multilineage differentiation potential and relationship to other mutations. Establishing this is essential not only for biologic understanding, but also to establish therapeutic endpoints in patients treated with mutant IDH inhibitors.
To address this we studied 23 patients presenting with AML or refractory anemia with excess blasts associated with mutations in IDH1 (n = 10) or IDH2 (n = 13) ( Supplementary Table S1 ), all of whom achieved complete morphological remission (CR) after one or two courses of induction chemotherapy. In each case there was reduction in IDH mutant allele frequency (MAF) by quantitative digital PCR (dPCR) following treatment. 8 However, samples collected at CR1 (after course 1 (n = 6) or 2 (n = 17)) demonstrated that only 3/23 (13%) had an undetectable IDH mutation burden (sensitivity ⩽ 0.1% MAF) ( Figure 1a ). Following consolidation chemotherapy IDH MAF variably decreased or increased ( Figure 1b ). Considering all patients at completion of chemotherapy, only 5/23 (22%) had undetectable IDH mut alleles (Figure 1c ). Thus IDH mut clones typically persist at the end of induction chemotherapy in the majority of patients achieving morphological CR and are not eradicated by consolidation chemotherapy.
By contrast, of seven patients receiving hematopoietic stem cell (HSC) transplant (including one transplanted in CR2), IDH mut alleles were undetectable in bone marrow in five (71%) by day 100 (Figure 1d ). Of these, three survive with undetectable IDH mut alleles 15, 22 and 51 months post transplant. One died in CR1 14 months post transplant of procedure-related complications with undetectable IDH1 R132C , and the fifth suffered graft failure, low-level reconstitution of IDH1 R132C -mutant hematopoiesis and died 22 months post transplant. Of the two others, one died of complications early post transplant and the other failed to clear IDH2 R172K following HSC transplant, heralding early relapse. Thus, in contrast to chemotherapy, allogeneic HSC transplant is effective in durable eradication of IDH mut hematopoiesis.
We next evaluated outcomes of 16 patients treated with chemotherapy alone for whom more than 6 months follow-up was available (including one subsequently transplanted in CR2). Three out of six IDH1 mut patients relapsed following a progressive rise in MAF, whereas three exhibit persistent low-level IDH1 mutant clones (o1% MAF) and remain in CR1 after 7, 22 and 24 months' follow-up, respectively (Supplementary Figure S1 ). Four of 10 IDH2 mut patients also relapsed, again following a progressive rise in MAF ( Figure 1e ). In contrast, six IDH2 mut patients (all with IDH2 R140Q mutations) remain in CR after 9-52 months' follow-up with normal or near-normal blood counts ( Supplementary Table S2 ) despite persistent and substantial IDH2 R140Q mutant clones, which in some cases dominate hematopoiesis ( Figure 1f ). As expected, plasma D-2hydroxyglutarate (D-2-HG) levels mirrored MAFs during CR ( Figure 1g ). 8 Thus, IDH2 R140Q mutant hematopoietic clones frequently persist and may predominate in patients with normal or near-normal hematopoiesis following successful chemotherapy for AML.
We next addressed the hierarchical placement of IDH mutations versus other known drivers in myeloid cancer using targeted next-generation sequencing in the 23 presentation samples ( Supplementary Table S1 ). We identified 109 high confidence somatic variants in 26 genes (median 4 per sample; range 2-9; Supplementary Figure S2 ; Supplementary Table S3 ) and confirmed the presence of all IDH mutations, with concordant MAFs versus dPCR (Supplementary Figure S3 ). The IDH mut clone was dominant in 12/23, a major sub-clone in 7/23 and a minor sub-clone in 4/23 cases (Figures 1h and i, Supplementary Figure S4 and Supplementary Table S3 ). Where dominant, the IDH MAF was similar to that of co-occurring mutations in 8/12 cases precluding identification of the ancestral mutation. However, in 4/12 cases (BB93, BB161, BB187 and BB484) the IDH MAF was larger, suggesting that mutations in IDH1 or IDH2 can predate mutations in SRSF2, JAK2 and DNMT3A. In 11 cases where the IDH mut clone was sub-clonal, the dominant clone exhibited mutations in DNMT3A (n = 6), SRSF2 (n = 5) or STAG2 (n = 1), indicating that in these instances mutations in IDH1 or IDH2 were secondary events. Sub-clonal placement of IDH mutations had no clear impact on the likelihood of persistence post-chemotherapy.
Sequencing of remission samples identified persistence in CR1 of mutations in DNMT3A, RUNX1, JAK2, ASXL1 and RAD21, in addition to those in IDH1 and IDH2. NPM1 and FLT3-ITD mutations were not detected in remission samples (Supplementary  Figures S4 and Supplementary Table S3 ). Illustrative of this, five IDH2 R140Q mutant patients who remain in long-term CR presented with a concomitant NPM1 mutation ( Supplementary Table S3 ). In each case the NPM1 mutation has remained undetectable despite persistence of the IDH2 mut clone ( Where the IDH MAF was proportionately 15% larger than that of any other mutation the clone was considered sole dominant; otherwise it was deemed co-dominant. Where the IDH MAF was 50-85% of that of the highest mutation, the IDH mut clone was considered a major sub-clone; otherwise it was deemed a minor sub-clone. BM, bone marrow; FISH, fluorescence in situ hybridization; RAEB, refractory anemia with excess blasts. in NPM1 (BB120, BB475) or RUNX1 (BB85, BB235, BB350) as determined by Sanger sequencing or digital PCR (data not shown). Thus mutations in SRSF2 and DNMT3A may precede or follow those in IDH1 or IDH2, whereas FLT3-ITD or mutations in NPM1 appear secondary and associated with the presence of frank leukemia.
To determine whether post-chemotherapy IDH2 R140Q clones contribute to multilineage hematopoiesis, we isolated by flowsorting phenotypically defined high-purity cell populations from the bone marrow and blood of two individuals in prolonged CR (Supplementary Figure S7) . In both patients neutrophils and monocytes were predominantly derived from IDH2 R140Q mutant clones, as was bone marrow erythropoiesis and myelopoiesis (Figures 2a and b) . The B-lineage was derived from an IDH2 R140Q clone predominantly in BB287 and to a lesser extent in BB161. The T-lineage was not involved. The immunophenotypic bone marrow HSC compartment exhibited 20-35% involvement with IDH2 R140Q mutant cells, with higher proportionate involvement of the downstream multipotent progenitor compartment in both cases. To interrogate further their functional potential, CD34 + hematopoietic stem and progenitor cells from deep remission time points from both patients were cultured in methylcellulose clonogenic assays. In keeping with our in vivo data, 96% and 50%, respectively, of individually isolated colonies (including both erythroid and granulocyte/macrophage colonies) were IDH2mutated (Figures 2d and e ), as were 60% of colonies derived from single flow-sorted immunophenotypic HSCs from BB287 (Figure 2f ). Similar analyses in a patient with persistent IDH1 mut hematopoiesis (BB355) 22 months after presentation demonstrated involvement of neutrophils and monocytes, but not lymphocytes (Supplementary Figure S8) .
In particular, our data demonstrate dynamic reconstitution of IDH2 R140Q -mutated, functionally normal, clonal hematopoiesis following successful chemotherapy for AML. Such clones may on occasion exhibit a concomitant SRSF2 P95R mutation. Our observations provide compelling in vivo evidence for the pre-leukemic nature of IDH2 R140Q mutations in view of their multilineage differentiation potential. These data extend insight into recent observations that immunophenotypic HSCs carry IDH mutations at diagnosis in 80% of IDH mut AMLs, 9 whilst xenografts from 36% of IDH mut AML patient samples generated non-leukemic multilineage grafts. 10 One unique feature of IDH mut AML is the generation of D-2-HG. This metabolite was present at high levels in the plasma of patients with persistent IDH mut clonal hematopoiesis (Figure 1g) , an observation which counters the concept that D-2-HG is directly transforming, as has recently been suggested. 11 Nevertheless, caution is mandated for the long-term outcome of these patients which to date remains unclear.
Importantly, our findings indicate that approaches tracking IDH mutations (or D-2-HG as their surrogate) will not reliably detect minimal residual leukemia, in contrast to recent claims. 12, 13 Further, total eradication of IDH mut clones (in particular IDH2 R140Q -mutant clones) as a therapeutic goal, for example using specific pharmacological inhibitors, while desirable, may not be necessary to achieve prolonged disease-free survival given that IDH mutations and leukemic disease are not tightly linked in many cases. That said, it remains unclear whether our conclusions extend to patients with IDH1 R132 or IDH2 R172 mutations because in our cohort persistence or recurrence usually heralded leukemic relapse, and the three cases with persistent IDH1 mut hematopoiesis display low MAFs. This hints at discrepant biology associated with different IDH mutations, in keeping with reported biochemical differences. 14 More broadly, our findings add IDH2 R140Q to DNMT3A, TET2 and other mutations as mediators of clonal hematopoiesis of indeterminate potential, 15 at least after chemotherapy for established AML. Colony-stimulating factor 2 receptor beta (CSF2RB) is the shared beta-chain receptor and essential signaling component for IL-3, IL-5 and GM-CSF receptor activation. In the context of GM-CSF signaling, the ligand-specific alpha chain (CSF2RA) complexes with CSF2RB and GM-CSF ligand, forming a dodecameric complex in which the proximity of CSF2RB subunits allows associated JAK2 kinases to transphosphorylate. 1 CSF2RB signals through several pathways including JAK2/STAT5, PI3K/mTOR and MEK/ERK to promote survival, proliferation and differentiation (reviewed in Hercus et al. 2 ). Both spontaneous transformation 3, 4 and random mutagenesis 4, 5 screens have shown that CSF2RB mutations can result in ligand-independent activation in vitro. However, these predicted oncogenic mutations have never been observed clinically. In fact, the only phenotypic CSF2RB mutations reported are recessive, loss-of-function, germline mutations in pulmonary alveolar proteinosis. 6 As oncology moves toward an age of personalized and molecularly targeted treatment it will require the identification and in vitro characterization of targetable genetic lesions. Here we describe the first case of a leukemia patient harboring a germline, CSF2RB-activating point mutation (R461C) and identify small-molecule inhibitors with therapeutic potential against this mutation. We obtained a pediatric T-cell acute lymphoblastic leukemia (T-ALL, Supplementary Figure 1a ) with informed consent approved by the Institutional Review Boards of Oregon Health & Science University and Erasmus University Medical Center, Sophia Children's Hospital. We isolated mononuclear cells and performed deep sequencing as previously described, 7 uncovering the CSF2RB R461C mutation at a 54% allele burden ( Supplementary Figures 1b and c) . The patient also presented with somatic NOTCH1-truncation, NOTCH1 missense and PTEN point mutations, which are all recurrent and leukemiaassociated mutations 8 (other observed mutations in Supplementary  Table 1 ). R461C was later confirmed by Sanger sequencing as a heterozygous, germline variant using a minimal residual disease day 79 sample for normal DNA (Supplementary Figure 1d) . CSF2RB R461C has never been previously described in cancer patients (including public databases) but is listed as a SNP in the 1000 Genomes database 9 (rs371045078) at a low-allele frequency (MAF = 0.000998, 5 observations in 1000 Genomes; 9 MAF = 0.000272, 33 observations in the Exome Aggregation Consortium 10 ) in exclusively heterozygous cases. Prior work has established that cancerpredisposing mutations exist in the germline of healthy individuals at frequencies as high as 1.1%, but those frequencies elevate to over 8% in children and adolescents with cancer, most of which demonstrate no family history of cancer. 11 Congenital mutations in CSF3R have also been observed to precede the development of acute myeloid leukemia. 12 In addition, there are numerous reports of families with gain-of-function germline mutations in receptors with similar biology as CSF2RB (for example, CSF3R, 13 EPOR 14 and MPL 15 ) and in many of these pedigrees the affected family members do not develop overt leukemia, though they sometimes exhibit elevated blood counts.
The location of this variant, within the putative membranespanning portion of the receptor, is of particular interest as this region is a hot spot for activating mutations in vitro. 5 Previously, mutations altering the number of membrane-spanning or membraneadjacent unpaired cysteines have been shown to activate the IL-7 receptor in T-ALL 16 and RET in medullary thyroid carcinoma. 17 CSF2RB has been shown to be partially activated in vitro by replacement of the extracellular domain with a short, cysteine-containing sequence. 4 Last, multiple sequence alignment of CSF2RB homologues demonstrated that arginine 461 is conserved across most mammals ( Supplementary Figure 2) increasing the potential that R461C could have functional relevance and cooperate with canonical leukemogenic mutations. Accordingly, we hypothesized that R461C could activate CSF2RB-signaling and contribute to the patient's leukemia.
We cloned CSF2RB R461C into the pMXs-IRES-Puro plasmid and transfected into IL-3-dependent murine Ba/F3 cells by electroporation. Stably transfected cells were selected using two weeks of continual 2 μg/ml puromycin selection prior to performing IL-3 withdrawal transformation assays as previously described. 7 R461C conferred factor-independent growth while wild-type (WT) CSF2RB did not (Figure 1a, Supplementary Figure 3 ). The full CSF2RB transgene was sequence confirmed in two biologically replicate, IL-3 independent cell lines and used for further studies.
We identified that CSF2RB R461C expression resulted in an accumulation of surface CSF2RB protein, relative to WT, prior to IL-3 withdrawal when assayed by flow cytometry ( Supplementary  Figure 4 ). Furthermore, immunoblot analysis showed that the R461C protein is significantly increased in IL-3-independent cells relative to WT cells grown in IL-3 (Figure 1b , details and all antibodies included in Supplementary Methods and Supplementary Table 2 ). As both exogenous versions of CSF2RB were expressed by identical promoters we rationalized that the accumulation was due to changes in CSF2RB protein stability. We performed time course experiments using 100 µg/ml cycloheximide in dimethyl sulfoxide followed by staining with PE-conjugated anti-CSF2RB to determine alterations in surface protein stability. The R461C mutant possessed a prolonged surface half-life relative to WT CSF2RB (6.5 vs 3.6 h; Figure 1c ). Given the presence of a novel cysteine and increased stability in the R461C mutant, we investigated disulfide-linked receptor oligomerization by immunoblot under nonreducing conditions. Comparing the WT-and R461C-expressing cells, we observed CSF2RB-containing complexes of~500 kDa that showed a reduced intensity when 2-mercaptoethanol was added to the lysate (normally CSF2RB runs at 125 kDa, Figure 1d ), indicating R461C enables novel disulfide interactions with additional CSF2RB monomers or other endogenous receptors.
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